Patent Publication Number: US-3881014-A

Title: N-tritylimidazoles for treating fungal infections

Description:
United States Patent Regel et al. Apr. 29, 1975 N-TRITYLIMIDAZOLES FOR TREATING [58] Field of Search 424/273 FUNGAL INFECTIONS [75] Inventors: Erik K. Regel, [56] References Cited Wuppertal-Kronenberg; Karl-Heinz UNITED STATES PATENTS Buchel, Leverkusen; Manfred 3,073,841 1/1963 Schindler 0; 260/309 P PP d. all of 3,321,366 5/1967 Mussell at al 260/309 Germany OTHER PUBLICATIONS [73] Asslgnee&#39; sa f gg g g g Fournari. et al., Bul. Soc. Chirn. France, June, 1968,  
  upper 21 er e ermany pp. 24384446 [22] Filed: June 22, 1973 Tolkmith et al., Science, Vol. 158, pp. l462-l463.  
 [21] Appl. No.: 372,780  
  Primary Exammer-Jerome D. Goldberg Related US. Application Data [62] Division of Ser. No. l87,8l4. Oct. 8, l97l. Pat. No. [57] ABSTRACT 3,824,310, which is a division of Ser. No. 873,098, OCL 31 1969 B1s-1midazolyl-bisphenylmethane and pharmaceutlcally acceptable non-toxic salts thereof are useful as [30] Foreign Application Priority Data antimycotics especially against dermatomycosis N 5 1968 G 1806995 caused by Trichophyton and Microsporium species and crmmy 1 also against yeast infections of the skin and internal 52 us. c1. .7 424/273 mgans [51 1 Int. Cl. H6lk 27/00 17 Claims, No Drawings N-TRITYLIMIDAZOLES FOR TREATING FUNGAL INFECTIONS This application is a divisional of our copending application Ser. No. 187,814 filed Oct. 8, 1971 now US. Pat. No. 3,824,310, which is a divisional of our priorfiled application Ser. No. 873,098 filed Oct. 31, 1969.  
  The present invention is concerned with bis-imidazolyl-bisphenylmethanes, salts thereof, processes for their production, pharmaceutical compositions containing such compounds and methods of treating fungal infections pathogenic to humans and animals and methods of treating yeast infections pathogenic to humans and animals. More particularly, the compounds of the present invention are bis-imidazolyl-bisphenylmethanes which may be substituted in&#39;one or both of the imidazolyl moieties and one or both of the phenyl moieties.  
  The compounds of the present invention are particularly useful as antimycotics especially against dermatomycosis caused by triclwphyton and microsporium species and also against yeast infections of the skin and internal organs.  
  The compounds of the present invention may be represented by the formula:  
 R ii R3 -i R 1 cx I Y wherein R is hydrogen, alkyl, aryl or substituted aryl,  
 R and R are the same or different and are hydrogen, alkyl, aryl, substituted aryl, or R and R together form a fused benzene ring,  
 X and y are the same or different and are an electronegative moiety, alkyl, S-alkyl or alkoxy,  
 m is 0, l or 2,  
 n is 0, l or 2,  
 and includes salts of such compounds.  
  When R, R or R is alkyl, it is preferred that the alkyl moiety contain from 1 to 4 carbon atoms. When it is aryl, it is preferred that the aryl moiety contain up to carbon atoms in the ring system and the preferred aryl moiety is phenyl. The aryl may be substituted in which event the preferred substituents are lower alkyl, S-alkyl or alkoxy, haloalkyl of 1 to 4 carbon atoms in the alkyl portion and preferably 1 or 2 carbon atoms in the alkyl portion and wherein the halogen is preferably fluorine, chlorine or bromine, or by an electronegative moiety, preferably a halogen.  
  When X or Y is alkyl, it is preferred that the alkyl moiety contain from 1 to 12 carbon atoms and preferably l to 4 carbon atoms. when it is S-alkyl or alkoxy,  
 it is preferred that the alkyl portions contain from 1 to 4 carbon atoms. When it is an electronegative moiety, it is preferred that the electronegative moiety be halogen, i.e., fluorine, chlorine, bromine or iodine, N0 CF or CN.  
  It is to be appreciated that when X or Yis more an one such moiety as above defined, such as in the case where m or n is 2, that the moieties may be the some or different.  
  The term alkyl includes straight chain and branched chain alkyl moieties as well as the saturated alkyl moieties and the partially unsaturated moieties, i.e., those containing a double bond.  
  The salts of the bis-imidazolyl-bisphenylmethanes of the present invention are preferably pharmaceutically acceptable non-toxic salts and examples of acids which give salts useful as hereinabove discussed include the halogen hydracids, phosphoric acids, monoand bifunctional carboxylic acids and hydroxycarboxylic acids, for example, acetic acid, propionic acid, maleic acid, succinic acid, fumaric acid, tartaric acid, citric acid, salicylic acid, sorbic acid and lactic acid and l,5-naphthalene-di-sulphonic acid. Of particular interest are the hydrohalides, particularly the chlorides, lactates and salicylates of the bis-imidazolylbisphenylmethanes.  
  According to a preferred embodiment of the present invention, R, R and R are hydrogen, X and Y are the same or different and are fluorine, chlorine, bromine, iodine, CN, N0 methoxy, thiomethyl or CF and m and n are l.  
  The bis-imidazolyl-bisphenylmethanes of the present invention may be produced by reacting a diphenyldihalomethane of the formula:  
 wherein X, Y, m and n are as above defined and wherein Hal is chlorine, bromine or iodine, with the stoichiometric amount of and imidazole derivative of the formula:  
  azole derivative may be used: however, the corresponding quantity of one of the conventional tertiary amines is preferably used, such as triethylamine, dimethylanilin, N,N-dimethyl-benzyl-amine and the like.  
  The starting materials used for the process of the present invention, i.e., the diphenyl-dihalomethanes of the formula (2) and the imidazole derivatives of the formula (3) are known or can be obtained according to methods and/or procedures per se known.  
 The following examples are representative of compounds of the formula (2):  
 Diphenyldichloromethane 2-fluoro-diphenyldichloromethane 3-fluoro-diphenyldichloromethane 4-fluoro-diphenyldichloromethane 2-chlor0-diphenyldichloromethane 3-chlor0-diphenyldichloromethane 4-chloro-diphenyldichloromethane 2-bromo-diphenyldichloromethane 3-bromo-diphenyldichloromethane 4-bromo-diphenyldichloromethane 2-nitro-diphenyldichloromethane 3-nitro-diphenyldichloromethane 4-nitro-diphenyldichloromethane 2-cyano-diphenyldichloromethane 3-cyano-diphenyldichloromethane 4-cyano-diphenyldichloromethane 2-methyl-diphenyldichloromethane 3-methyl-diphenyldichloromethane 4-methyl-diphenyldichloromethane 2-ethyl-diphenyldichloromethane 3-ethyl-diphenyldichloromethane 4-ethyl-diphenyldichloromethane 2-methoxy-diphenyldichloromethane 3-methoxy-diphenyldichloromethane 4-methoxy-diphenyldichloromethane 2-methyl-thio-diphenyldichloromethane 3-methyl-thio-diphenyldichloromethane 4-methyl-thio-diphenyldichloromethane 2-methyl-sulphinyl-diphenyldichloromethane 3-methyl-sulphinyl-diphenyldichloromethane 4-methyl-sulphinyl-diphenyldichloromethane 2-methyl-sulphonyl-diphenyldichloromethane 3-methyl-sulphonyl-diphenyldichloromethane 4-methyl-sulphonyl-diphenyldichloromethane 4-tert.butyldiphenyldichloromethane 4-phenyl-diphenyldichloromethane 2,4-dichloro-diphenyldichloromethane 2,5-dichloro-diphenyldichloromethane 3,4-dichloro-diphenyldichloromethane 4-chloro-2-nitro-diphenyldichloromethane 4-chloro-3-nitro-diphenyldichloromethane 6-chloro-3-nitro-diphenyldichloromethane 2-chlor0-4-nitro-diphenyldichloromethane 2,4-dinitro-diphenyldichloromethane 3,4-dinitro-diphenyldichloromethane 3,5-dinitro-diphenyldichloromethane 4-nitro-3-methyl-diphenyldichloromethane 3-nitro-4-methyl-diphenyldichloromethane 2,2&#39;-difluoro-diphenyldichloromethane 2 ,3 &#39;-difluoro-diphenyldichloromethane 2,4&#39;-difluoro-diphenyldichloromethane 3,3&#39;-difluor0-diphenyldichloromethane 3,4&#39;-difluoro-diphenyldichloromethane 4,4-difluor-diphenyldichloromethane 2-fluoro-2&#39;-chl0ro-diphenyldichloromethane 2-fluoro-3 -chloro-diphenyldichloromethane 2-fluoro-4&#39;-chloro-diphenyldichloromethane 3-fluoro-3 &#39;-chloro-diphenyldichloromethane 3-fluoro-4&#39;-chloro-diphenyldichloromethane 4-fluoro-4&#39;-chloro-diphenyldichloromethane 4-fluoro-4&#39;-bromo-diphenyldichloromethane 2,2&#39;-dichloro-diphenyldichloromethane 2,3 &#39;-dichl0ro-diphenyldichloromethane 2,4-dichloro-diphenyldichloromethane 3,3&#39;-dichloro-diphenyldichloromethane 3,4-dichloro-diphenyldichloromethane 4,4&#39;-dichloro-diphenyldichloromethane 2-chloro-4&#39;-bromo-diphenyldichloromethane 3-chloro-4-bromo-diphenyldichloromethane 4-chloro-4&#39;-bromo-diphenyldichloromethane 4-fluoro-2&#39;-nitro-diphenyldichloromethane 4-fluor0-3&#39;-nitro-diphenyldichloromethane 4-fluoro-4-nitro-diphenyldichloromethane 4-chloro-2&#39;-nitro-diphenyldichloromethane 4-chloro-3 -nitro-diphenyldichloromethane 4-ehloro-4&#39;-nitro-diphenyldichloromethane 4-bromo-2&#39;-nitro-diphenyldichloromethane 4-bromo-3&#39;-nitro-diphenyldichloromethane 4-bromo-4&#39;-nitro-diphenyldichloromethane 4-fluoro-4&#39;-cyano-diphenyldichloromethane 4-chloro-4&#39;-cyano-diphenyldichloromethane 4-bromo-4&#39;-cyano-diphenyldichloromethane 2-methyl-2&#39;-fluoro-diphenyldichloromethane 2-methyl-3 &#39;-fluoro-diphenyldichloromethane 2-methyl-4&#39;-fluoro-diphenyldichloromethane 2-methyl-2-chloro-diphenyldichloromethane 2-methyl-3 &#39;-chlor0-diphenyldichloromethane 2-methyl-4&#39;-chlor0-diphenyldichloromethane 3-methyl-2&#39;-fluoro-diphenyldichloromethane 3-methyl-3 &#39;-fluoro-diphenyldichloromethane 3-methyl-4&#39;-fluoro-diphenyldichloromethane 3-methyl-2&#39;-chloro-diphenyldichloromethane 3-methyl-3 &#39;-chloro-diphenyldichloromethane 3-methyl-4&#39;-chloro-diphenyldichloromethane 4-methyl-2&#39;-chloro-diphenyldichloromethane 4-methyl-3 &#39;-chlor0-diphenyldichloromethane 4-methyl-4&#39;-chloro-diphenyldichloromethane 4-tert.-butyl-2&#39;-fluoro-diphenyldichloromethane 4-tert.-butyl-3 &#39;-fluoro-diphenyldichloromethane 4-tert.-butyl-4&#39;-fluoro-diphenyldichloromethane 4-tert.-butyl-2&#39;-chloro-diphenyldichloromethane 4-tert.-butyl-3 -chloro-diphenyldichloromethane 4-tert.-butyl-4&#39;-chloro-diphenyldichloromethane 2,4-dichloro-2&#39;-fluor0-diphenyldichloromethane 2,4-dichloro-3 &#39;-fluoro-diphenyldichloromethane 2,4-dichloro-4&#39;-fluoro-diphenyldichloromethane 2,4-dichloro-2&#39;-chloro-diphenyldichloromethane 2,4-dichloro-3 -chloro-diphenyldichloromethane 2,4-dichloro-4-chloro-diphenyldichloromethane 2,5-dichloro-2&#39;-fluoro-diphenyldichloromethane 2,5-dichloro-3 &#39;-fluoro-diphenyldichl0romethane 2,5-dichloro-4&#39;-fluoro-diphenyldichloromethane 2,5-dichloro-2&#39;-chloro-diphenyldichloromethane 2,5-dichloro-3 &#39;-chloro-diphenyldichloromethane 2,5-dichloro-4&#39;-chloro-diphenyldichloromethane 3 ,4-dichloro-2 -fluoro-diphenyldichloromethane 3 ,4-dichloro-3 &#39;-fluor0-diphenyldichloromethane 3 ,4-dichloro-4&#39;-fluoro-diphenyldichloromethane 3,4-dichloro-2&#39;-chloro-diphenyldichloromethane 3 ,4-dichloro-3 &#39;-chloro-diphenyldiehloromethane 3,4-dichlor0-4&#39;-chloro-diphenyldichloromethane 4-chloro-2&#39;-fluoro-2-nitro-diphenyldichloromethane 4-chloro-3 &#39;-fluoro-2-nitro-diphenyldichloromethane 4-chloro-4-fluoro-2-nitro-diphenyldichloromethane 4-chloro-2&#39;-chloro-2-nitr0-diphenyldichloromethane 4-chloro-3 &#39;-chloro-2-nitro-diphenyldichloromethane 4-chloro-4&#39;-chloro-2-nitro-diphenyldichloromethane 4-chloro-2&#39;-fluoro-3-nitro-diphenyldichloromethane 4-chloro-3 &#39;-fluoro-3-nitro-diphenyldichloromethane 4-chloro-4-fluoro-3-nitrodiphenyldichloromethane 4-chloro-2&#39;-chloro-3-nitro-diphenyldichloromethane 4-chloro-3 &#39;-chloro-3nitro-diphenyldichloromethane 4-chloro-4&#39;-chloro-3-nitro-diphenyldichloromethane 6-chloro-4&#39;-fluoro-3-nitro-diphenyldichloromethane 6-chloro-4-chloro-3-nitro-diphenyldichloromethane 2-chloro-4&#39;-chloro-4-nitro-diphenyldichloromethane 2-chloro-4&#39;-fluoro-4-nitro-diphenyldichloromethane 4-chloro-2&#39;,4&#39;-dinitro-diphenyldichloromethane 4-chloro-3 ,4-dinitro-diphenyldichloromethane 4-chloro-3 &#39;,5 &#39;-dinitro-diphenyldichloromethane 4-chloro-3&#39;-methyl-4-nitrodiphenyldichloromethane 4-chloro-4 -methyl-3 -nitrodiphenyldichloromethane 2,2,5,5&#39;-tetrachloro-diphenyldichloromethane 2-fluoro-4&#39;-methoxy-diphenyldichloromethane 3 -fluoro-4 &#39;-methoxy-diphenyldichloromethane 4-fluoro-4&#39;-methoxy-diphenyldichloromethane 2-chloro-4&#39;-methoxy-diphenyldichloromethane 3-chloro-4&#39;-methoxy-diphenyldichloromethane 4-chloro-4&#39;-methoxy-diphenyldichloromethane 2-methy1-4&#39;-methoxy-diphenyldichloromethane 3-methyl-4&#39;-methoxy-diphenyldichloromethane 4-methyl-4-methoxy-diphenyldichloromethane 2-fluoro-4-methylthio-diphenyldichloromethane 3-fluoro-4-methylthio-diphenyldichloromethane 4-fluoro-4 &#39;-methylthio-diphenyldichloromethane 2-chloro-4-methylthio-diphenyldichloromethane 3-chloro-4&#39;-methylthio-diphenyldichloromethane 4-chloro-4&#39;-methy1thio-diphenyldichloromethane 2,4-dichloro-4-methylthiodiphenyldichloromethane 2,5-dichloro-4&#39;-methylthiodiphenyldichlorom ethane 3,4-dichloro-4&#39;-methylthiodiphenyldichloromethane 2,4-dichloro-4&#39;-methoxy-diphenyldichloromethane 2,5-dichloro-4&#39;-methoxy-diphenyldichloromethane 3 ,4-dichloro-4 &#39;-methoxy-diphenyldichloromethane 4-ethylthio-2-chloro-diphenyldichloromethane 4-ethylsu1phonyl-2-chloro-diphenyldichloromethane The following examples are representative of compounds of the formula (3);  
  imidazole 2-methylimidazole 2-ethylimidazole 2-phenylimidazole 4,(5 )-phenylimidaz0le 4,5-diphenylimidazole benzimidazole Salts of compounds of the formula (1 may be converted into their corresponding salts by techniques per se known. For example, 0.2 mol of a bis-imidazolylbisphenylmethane may be dissolved with heating in acetonitrile, followed by the addition of 0.22 ml D,L- lactic acid. The residue remaining after the solvent has been distilled off may be made to crystallize by covering it, after filtration, with a layer of ether; the crystalline product may be washed with ether and dried.  
  The hydrochlorides are expediently obtained by introducing hydrogen chloride into the solution of the imidazole derivative, for example, in carbon tetrachloride.  
  there are added dropwise 55 g (0.21  
  The following table shows examples of the compounds of the invention:  
 a) bis-imidazolyl-bis-phenylmethane I b) bis-imidazolyl-4-chlorophenyl-phenylmethane I40 c) bis-imidazolyl-4-fluorophenyl-phenylmethane l 30 d) bis-imidazolyl-2,4&#39;-difluoro-diphenylmethane 129 e) bis-imidazolyLZ-chlorophenyl-phenylmethane I43 f) bis-imidazolyl-3-chlorophenyl-phenylmethane 1 18 g) bis-imidazolyl-4-cyanophenyl-phenylmethane h) bis-( 2-methylimidazolyl )-4-chlorophenylphe&#39;nylmethane 215 The compounds and salts of the formula (1) can be used, inter alia, in the form of an aqueous emulsion, suspension or solution. It is also possible to use the aqueous solutions of the salts of the above compounds.  
  The invention is illustrated by the following Examples.  
 EXAMPLE 1 Bis-imidazolyl-4-chlorophenyl-phenylmethane To a solution of 27.2 g (0.4 mol) imidazole and 40.4 g (0.4 mol) triethylamine in 300 ml acetonitrile there are added dropwise 54 g (0.2 mol) 4-chloropheny1- phenyl-dichloromethane. The triethylamine hydrochloride formed starts to separate at room temperature. The mixture is heated at 80C for 12 hours to complete the reaction. After cooling, the reaction mixture is stirred with 500 ml benzene and washed with water until free of salt. The benzene solution is dried over anhydrous sodium sulphate, filtered and concentrated by evaporation; after recrystallisation of the crude prod uct from acetonitrile, there result 41 g of pure bisimidazolyl-4-ch1orophenyl-phenylmethane of mp. C.  
 CIQHI5CIN4 mol. weight 334.5  
 Calculated: C. 68.0%; H 4.5%; Cl 10.6%; N 16.7%. Found: C, 68.0% H 4.8%; CI 10.7%; N 16.9%.  
  The same compound is obtained when, as starting compound, the dichloromethane compound is replaced by 4-chlorophenyl-phenyl-dibromomethane or the corresponding diiodine compound.  
 EXAMPLE 2 Bis-imidazolyl-4-fluorophenyl-phenylmethane Into a solution of 29.4 g (0.43 mol) imidazole and 43.7 g (0.43 mol) triethylamine in 300 ml acetonitrile mol) 4- C ll FN mol. weight 318 Calculated: C. 71.8%; H 4.7%; F 6.0%; N l7.6%. Found: H 4.9%. F 6.0%. N 17.6%.  
  The following compounds of the formula (4) are prepared in a manner analogous to that set forth in Example 2 by reacting the appropriate diphenyldichloromethane from the list on pages 7 to 12 with the appropriate imidazole set forth on page 12.  
 EXAMPLES 3 9 X m.p.C  
  4 5 3-Cl i11 6 4-CN 125 7 4Br 137 x 4 NO 163 8a 4-CH, O 122 8b 3-N0 4-Cl 207 8c 3-N0 4--C1-1 166 8d 2.s c 140 9 4F 130 The following compounds of the formula (5) are prepared in a manner analogous to that set forth in Example 2 by reacting the appropriate diphenyldichloromethane from the list on pages 7 to 12 with the appropriate imidazole set forth on page 13.  
 EXAMPLES l0 15 1 It Y X Y m.p.&#34;C 10 2-F 4F 129 11 4F 4-4 I96 12 4F 4Cl I83 13 4Cl 4Cl I98 14 4F 4N0z I98 15 4F 4-CN 190 The following compounds of the formula (6) are prepared in a manner analogous to that set forth in Exampics 1 and 2 by reacting the appropriate diphenyldichloromethane from the list on pages 7 to 12 with the appropriate imidazole set forth on page 13.  
 EXAMPLES l6 34 THERAPEUTIC UTILITY l. Effectiveness in vitro against human-pathogenic fungi II. In vivo activity Taking as example white mice infected i.v. with Candida nlbicans and Aspergillus fumigatus, the new compounds [e.g., (a) to (h)], given orally in doses of 50100 mg/kg body weight once or twice daily over 5 I days, show good curative effects. Dependent upon the dosage. the rate of survival of the animals thus treated amounted to 50 to percent, of the untreated control animals 0 to l0 percent.  
  With the same dosage scheme and a therapy duration of 8 to 10 days, the development of dermatomycoses caused by Trichophyton and Microsporium species can be inhibited in mice and guinea pigs in an average of 70 percent of the infected animals; in comparison with the untreated-control group, the infection proceeds in the remaining 30 percent mildly and adheres for only a short period of time.  
  The topical-therapeutic application in the form of ointments and tinctures with a 1 percent content of active ingredient leads in guinea pigs infected with dermatophytes to healing of the mycosis within 6 to 8 days post infection whereas in untreated control animals the dermatomycosis has an average duration of 28 to 31 days.  
  Similar results are obtained when, instead of the compounds (a) to (h), the other new compounds or salts are used.  
  Of special interest for practical use are the compounds which are unsubstituted on the imidazole ring, but which may be substituted in one phenyl moiety by a halogen atom (preferably chlorine, fluorine, in the o-, mor p-position, i.e., 2-, 3- or 4-position) as well as their salts with hydrochloric acid, lactic acid or salicylic acid.  
  It is particularly envisaged that the compounds of the present invention may be used in the following manner; a. In human medicine:  
 1. Dermatomycoses caused by fungi of the species Trichvphyres, Microporium, Epidermophytes, Aepergillus, Candida albicans, and other yeasts.  
 2. Organomycoses caused by yeasts, mould fungi and dermatophytes.  
 b. In veterinary medicine:  
 Dermatomycoses and Organomycoses caused by yeasts, mould fungi and dermatophytes. The therapeutical application can be effected orally or parenterally as well as topically in the form of solutions (e.g., dimethyl sulphoxide/glycerol/water 222:6), alcohol, preferably ethanol and isopropanol, buffer solutions, powders, dreams, ointments and tablets. For topical application preferably a concentration of about from 0.5 to 10 percent of effective ingredient is used.  
  For humans the dosage amounts on average to between about 50 and about 100 mg/kg body weight, preferably 50 to about 80 mg/kg body weight, at intervals of up to 12 hours for the duration of about 8 to about 10 days.  
  However, it may of course be found desirable in some cases to deviate from the quantities indicated here, not only depending on the method of application, but also on possible variations in individual reactions to the compound or the kind of formulation and on the time or the interval at which it is administered. It may thus be possible to manage with less than the abovementioned minimum amount in some cases, whereas in other cases the indicated upper limit may have to be exceeded. If larger quantities are administered, it may be advisable to distribute these in several individual doses over the day.  
 carriers, are the following: tablets, capsules, powders,  
 with sweetening additives and other conventional substances. The therapeutically active compound should generally be present at a concentration of about 0.5 to per cent by weight of the total mixture, in quantities which are sufficient to achieve the dosage range mentioned above.  
  For oral application, the tablets can obviously also contain additives, such as sodium citrate, calcium carbonate and dicalcium phosphate together with various other additives, such as starch, preferably potato starch, and the like, and binding agents, such as polyvinyl-pyrrolidone, gelatin and the like. Lubricants, such as magnesium stearate, sodium lauryl sulphate and talc may also be used concurrently for the production of the tablets. In the case of aqueous suspension and/or elixirs which are intended for oral use, the active substance may be provided with various agents to improve the flavour, colouring substances, emulsifiers and/or with diluents, such as water, ethanol, propylene glycol, glycerol and similar compounds or combinations.  
  For parenteral application, solutions of the active substances in sesame or peanut oil, or in aqueous propylene glycol or N,N-dimethyl formamide can be employed as well as sterile aqueous solutions in the case of water-soluble compounds. Aqueous solutions of this kind should be buffered in the usual manner if necessary; furthermore, the liquid diluent should be rendered isotonic from the start by the addition of the necessary amount of salt or glucose. Such aqueous solutions are particularly suitable for intravenous, intramuscular and intraperitoneal injections.  
  Sterile aqueous media of this kind are prepared in known manner.  
  In mice, rats, rabbits, dogs and cats the LD of the compounds mentioned above ranges from about 500 and 1,000 mg/kg body weight when orally administered.  
  The present invention also includes pharmaceutical compositions comprising one or more compounds as hereinbefore described as the active ingredient in combination with a pharmaceutically acceptable non-toxic inert diluent or carrier.  
  The present invention further provides a medicament in unit dosage form which comprises at least one of the compounds hereinbefore described either alone or in combination with a pharmaceutically acceptable inert diluent or carrier. The medicament may include a protective envelope containing the active compound and if used the diluent or carrier.  
  The term medicament in dosage unit form&#34; as used in the present specification means as medicament as defined above in the fonn of discrete portions each containing a unit dose, or a multiple or sub-multiple of a unit dose of the active compound or compounds. Such portions may, for example, be in monolithic coherent form, such as tablets, suppositories, pills or dragees; in wrapped or concealed form, such as wrapped powders, cachets, sachets, or capsules; in ampoules, either free or as a sterile solution suitable for parenteral injection; or in any other form known to the an.  
  Besides the antimycotic activity the compounds show an activity against pathogenic protozoa, e.g., Trypanosoma, Trichomonas, Entamoeba histolytica, malaria parasites, Toxoplasma and against bacteria, e.g., Staphylocci, Streptococci, Klebsiella, E. coli.  
  Further the compounds activate the granulation in wound healing and show a hypocholesterinaemic activity.  
 What is claimed:  
  1. A pharmaceutical composition in the form of a tablet, a capsule, a powder, a spray, a sterile aqueous suspension, an injectable solution, an elixir, a syrup or a suppository useful for treating fungal infections pathogenic to humans or animals which comprises an antifungal amount of a compound of the formula wherein R is hydrogen or alkyl of l to 4 carbon atoms;  
 X and Y are alkyl of l to 4 carbon atoms; and  
 m is 0, l or 2, and  
  n is 0, l or 2; or a pharmaceutically acceptable non-toxic salt thereof, in combination with a pharmaceutically acceptable nontoxic inert diluent or carrier.  
  2. A pharmaceutical composition according to claim 1 wherein R is hydrogen.  
  3. A pharmaceutical composition according to claim 2whereinmis0,lor2andnis1or2;ormislor2 and n is O, l or 2.  
  4. A pharmaceutical composition according to claim 1 wherein X and Y are methyl.  
  5. A pharmaceutical composition according to claim 1 wherein R is hydrogen and m is and n is 0.  
  6. A pharmaceutical composition according to claim 1 in oral administration form.  
  7. A pharmaceutical composition according to claim I in parenteral administration form.  
  8. A pharmaceutical composition according to claim 1 in a form suitable for topical application.  
  9. A method of treating fungal infections pathogenic to humans or animals which comprises administering to a human or animal in need of said treatment an antifungal amount of a compound of the formula R is hydrogen or alkyl of l to 4 carbon atoms;  
 X and Y are alkyl of l to 4 carbon atoms; and  
 m is 0, l or 2, and  
  n is O, l or 2; or a pharmaceutically acceptable non-toxic salt thereof.  
  10. A method according to claim 9 wherein R is hydrogen.  
  11. A method according to claim 10 wherein m is 0, l or2andnis l or2;ormis l or2andnis0, l or2.  
  12. A method according to claim 9 wherein X and Y are methyl.  
  13. A method according to claim 9 wherein R is hydrogen and m is 0 and n is 0.  
  14. A method according to claim 9 wherein said administration is in dosage unit form.  
  15. A method according to claim 9 wherein said administration is oral.  
  16. A method according to claim 9 wherein said administration is parenteral.  
  17. A method according to claim 9 wherein said administration is by topical application.